Sanofi muscled Novo Nordisk out of the way to buy Ablynx ... Spain's Enagas fell 3.8 per cent after Kepler Cheuvreux cut its target price on the stock.
Sanofi shares were down 2.3 percent in early session trading, making the stock the worst performer on France’s benchmark CAC-40 index. Sanofi also underperformed a flat performance on the STOXX Europe 600 Healthcare index. …
(http://on.wsj.com/2mYJulp) The price represents a 64 percent premium to Bioverativ stock's close on Friday on the Nasdaq. Bioverativ, a hemophilia drug maker, was separated from Biogen Inc early last year. Sanofi has failed to land …
(ShareCast News) - Shares in Belgian biotech company Ablynx surged on Monday after it agreed to be bought by French pharmaceutical group Sanofi for €45 per share in cash, or €3.9bn. Novo Nordisk, which offered up to €30.50 per share …
But investors were not convinced, sending Sanofi's shares sharply lower in early business on the Paris stock exchange as they wondered about the wisdom of putting so much money on the table. The deal "looks logical, but expensive", with …
PARIS — France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases. The deal announced Monday is the latest such move in a …
The price represents a 64% premium to Bioverativ stock’s close on Friday on the Nasdaq. Bioverativ, a hemophilia drug maker, was separated from Biogen Inc early last year. Sanofi has failed to land major deals after losing California …